Nuveen Asset Management LLC Raises Position in Codexis, Inc. (NASDAQ:CDXS)

Nuveen Asset Management LLC grew its holdings in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 18.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,812,345 shares of the biotechnology company's stock after buying an additional 283,760 shares during the quarter. Nuveen Asset Management LLC owned 2.23% of Codexis worth $8,645,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Summit Investment Advisors Inc. grew its stake in shares of Codexis by 81.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company's stock valued at $40,000 after buying an additional 3,783 shares during the last quarter. Fiduciary Trust Co bought a new position in shares of Codexis during the fourth quarter valued at approximately $65,000. Group One Trading LLC bought a new position in shares of Codexis during the fourth quarter valued at approximately $73,000. Kingswood Wealth Advisors LLC bought a new position in shares of Codexis during the fourth quarter valued at approximately $79,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Codexis during the fourth quarter valued at approximately $82,000. Institutional investors own 78.54% of the company's stock.

Codexis Trading Down 2.2%

NASDAQ:CDXS traded down $0.05 during midday trading on Monday, hitting $2.25. The stock had a trading volume of 869,774 shares, compared to its average volume of 701,241. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The company has a market capitalization of $186.40 million, a price-to-earnings ratio of -2.59 and a beta of 2.56. The stock has a 50-day moving average of $2.36 and a 200 day moving average of $3.62. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). The company had revenue of $7.54 million for the quarter, compared to the consensus estimate of $10.38 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. As a group, sell-side analysts forecast that Codexis, Inc. will post -0.77 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised Codexis to a "sell" rating in a research note on Friday, May 16th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.